Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.54 |
| ▸ | JAK2 | O60674 | 12/20 | 0.54 |
| ▸ | JAK1 | P23458 | 12/20 | 0.54 |
| ▸ | TYK2 | P29597 | 2/20 | 0.50 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22097689 | 1.00 | JAK3 (0.54) | JAK3JAK2JAK1TYK2TBK1 | |
| SCHEMBL22089943 | 1.00 | JAK3 (0.54) | JAK3JAK2JAK1TYK2TBK1 | |
| SCHEMBL29941682 | 1.00 | JAK3 (0.54) | JAK3JAK2JAK1TYK2TBK1 | |
| SCHEMBL29942279 | 1.00 | JAK3 (0.54) | JAK3JAK2JAK1TYK2TBK1 | |
| SCHEMBL28618372 | 0.94 | DDR2 (0.51) | JAK3JAK2JAK1DDR2 | |
| SCHEMBL22089894 | 0.94 | DDR2 (0.51) | JAK3JAK2JAK1DDR2 | |
| SCHEMBL29941768 | 0.94 | DDR2 (0.51) | JAK3JAK2JAK1DDR2 | |
| SCHEMBL22089914 | 0.92 | JAK3 (0.54) | JAK3JAK2JAK1TYK2TBK1 | |
| SCHEMBL28602200 | 0.92 | JAK3 (0.54) | JAK3JAK2JAK1TYK2TBK1 | |
| SCHEMBL24853586 | 0.92 | JAK2 (0.49) | JAK3JAK2JAK1DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113227074-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods | 凌科药业(杭州)有限公司 | 2021-08-06 | — | — | CN | claimed |
| CN-118290403-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240083881-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-03-14 | — | — | US | disclosed |
| CN-113227074-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods | 凌科药业(杭州)有限公司 | 2021-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083881-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.